P2, N=66, Active, not recruiting, Ontario Clinical Oncology Group (OCOG) | Trial completion date: Apr 2026 --> Jul 2026

P=N/A, N=280, Not yet recruiting, Qilu Hospital of Shandong University

P4, N=100, Not yet recruiting, GlaxoSmithKline

P1/2, N=68, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

P2, N=58, Active, not recruiting, University of Texas Southwestern Medical Center | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jul 2026 --> Jul 2027

These findings provide translational validation for PD1-IL2v's mechanism, demonstrating selective intra-tumoral immune stimulation while minimizing Treg activation. This characterization identifies PD-1 receptor density and subset prevalence as critical factors for drug activity and represents potentially useful biomarkers for predicting patient responsiveness and guiding patient selection.

P2/3, N=137, Recruiting, Merck Sharp & Dohme LLC

P2/3, N=126, Not yet recruiting, AstraZeneca AB

P1/2, N=30, Not yet recruiting, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

The time-dependent ROC AUC at both the level of IL-1ra and frequency of CD8(+)CD45RO(+)CD27(+)CD127(+) T cells significantly predict OS (p = 0.0193 and p = 0.0442). These preliminary findings indicated that localized non-ablative irradiation against metastatic lymph node has a potential to enhance the clinical efficacy of anti-PD-1 immunotherapy in patients with m-GC, and IL-1ra level and frequency of CD8(+)CD45RO(+)CD27(+)CD127(+) T cells in peripheral blood before treatment may be candidate biomarkers to predict clinical efficacy of Nivo-lRT_mLN.

P1, N=300, Enrolling by invitation, M.D. Anderson Cancer Center | Recruiting --> Enrolling by invitation

P=N/A, N=440, Recruiting, BeOne Medicines